These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33799005)

  • 1. The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer.
    Rizzo A
    Cancer Treat Res Commun; 2021; 27():100360. PubMed ID: 33799005
    [No Abstract]   [Full Text] [Related]  

  • 2. Pursuing efficacious systemic therapy for hepatocellular carcinoma.
    Cheng AL
    Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):95-96. PubMed ID: 33408363
    [No Abstract]   [Full Text] [Related]  

  • 3. Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers.
    Harris WP; Wong KM; Saha S; Dika IE; Abou-Alfa GK
    Semin Oncol; 2018 Jun; 45(3):116-123. PubMed ID: 30348531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.
    Rizzo A; Ricci AD; Brandi G
    Future Oncol; 2021 Mar; 17(7):755-757. PubMed ID: 33508960
    [No Abstract]   [Full Text] [Related]  

  • 5. New systemic agents for hepatocellular carcinoma: an update 2020.
    von Felden J
    Curr Opin Gastroenterol; 2020 May; 36(3):177-183. PubMed ID: 32101985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic and targeted therapy for biliary tract tumors and primary liver tumors.
    Thomas MB
    Surg Oncol Clin N Am; 2014 Apr; 23(2):369-81. PubMed ID: 24560115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T; Pang R; Chan P; Poon RT
    Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.
    DeLeon TT; Ahn DH; Bogenberger JM; Anastasiadis PZ; Arora M; Ramanathan RK; Aqel BA; Vasmatzis G; Truty MJ; Oklu R; Bekaii-Saab TS; Borad MJ
    Future Oncol; 2018 Mar; 14(6):553-566. PubMed ID: 29460642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.
    Sharma R; Motedayen Aval L
    Front Immunol; 2021; 12():652007. PubMed ID: 33790915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving treatment landscape of advanced urothelial carcinoma.
    Andreev-Drakhlin AY; Egoryan G; Shah AY; Msaouel P; Alhalabi O; Gao J
    Curr Opin Oncol; 2021 May; 33(3):221-230. PubMed ID: 33818541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Shin H; Lee JH
    Lancet; 2024 Aug; 404(10453):654-655. PubMed ID: 39153810
    [No Abstract]   [Full Text] [Related]  

  • 12. Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Donadon M; Di Martino M; Rigamonti C
    Lancet; 2024 Aug; 404(10453):655-656. PubMed ID: 39153812
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Chen Z; Lan X; Du C; Xiao H
    Lancet; 2024 Aug; 404(10453):656. PubMed ID: 39153813
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Rose S; Ashraf MU; Premkumar M
    Lancet; 2024 Aug; 404(10453):656-657. PubMed ID: 39153814
    [No Abstract]   [Full Text] [Related]  

  • 15. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
    Wang Y; Jiang M; Zhu J; Qu J; Qin K; Zhao D; Wang L; Dong L; Zhang X
    Biomed Pharmacother; 2020 Dec; 132():110797. PubMed ID: 33068935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of sorafenib in hepatocellular carcinoma.
    Gholam P
    Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
    [No Abstract]   [Full Text] [Related]  

  • 17. Evolution of Systemic Therapy for Hepatocellular Carcinoma.
    Finn RS; Zhu AX
    Hepatology; 2021 Jan; 73 Suppl 1():150-157. PubMed ID: 32380571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.
    Armstrong SA; He AR
    Clin Liver Dis; 2020 Nov; 24(4):739-753. PubMed ID: 33012456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there any place for novel agents in treating biliary tract cancer?
    Perego G; Burgio V; Nozza R; Longobardo G; Bernecich M; Luciani A; Petrelli F
    Med Oncol; 2021 Feb; 38(2):19. PubMed ID: 33543377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation.
    Zhuang L; Mou HB; Yu LF; Zhu HK; Yang Z; Liao Q; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Feb; 19(1):91-93. PubMed ID: 31706859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.